SpringerLink
Log in

Side Effects of Antiepileptic Drugs

  • Protocol
  • First Online:
Antiepileptic Drug Discovery

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

Adverse effects of antiepileptic drugs (AEDs) are common and result in treatment discontinuation in up to 25 % of patients. The profile of adverse effects varies greatly among AEDs and markedly affects drug selection for individual patients. The most common adverse effects like cognitive impairment, coordination difficulties, and other CNS-related adverse effects are predictable, dose dependent, and reversible. They are of particular concern in patients who work or study. Idiosyncratic adverse reactions are unexpected events that cannot be explained by known mechanisms of action. Typically, they are not related to dose and they are associated with high risk of morbidity or even mortality. Some of them, like weight gain, can negatively affect treatment adherence. Many of AEDs increase the risk of congenital malformations or reproductive problems. New AEDs are usually better tolerated and some of them have no effect on hepatic drug-metabolizing enzymes which results in lower potential for drug interactions. Comparative, well-designed, and long-term trials are however needed to confirm better tolerability of the new AEDs and to assess their effect on quality of life, tolerability, and teratogenic potential.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now
Protocol
EUR 44.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 85.59
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 117.69
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 106.99
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Perucca P, Carter J, Vahle V et al (2009) Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 72:1223–1229

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Perucca P, Gilliam FG (2012) Adverse effects of antiepileptic drugs. Lancet Neurol 9:792–802

    Article  CAS  Google Scholar 

  3. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259

    Article  CAS  PubMed  Google Scholar 

  4. Gilliam F (2002) Optimizing health outcomes in active epilepsy. Neurology 58(Suppl 5):S9–S20

    Article  PubMed  Google Scholar 

  5. Ketter TA, Post RM, Theodore WH (1999) Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53(Suppl 2):S53–S67

    CAS  PubMed  Google Scholar 

  6. Reijs R, Aldenkamp AP, De Krom M (2004) Mood effects of antiepileptic drugs. Epilepsy Behav 5(Suppl 1):S66–S76

    Article  PubMed  Google Scholar 

  7. Téllez-Zenteno JF, Dhar R, Hernandez-Ronquillo L et al (2007) Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 130:334–345

    Article  PubMed  Google Scholar 

  8. Besag FM (2001) Behavioural effects of the new anticonvulsants. Drug Saf 24:513–536

    Article  CAS  PubMed  Google Scholar 

  9. Franks RD, Richter AJ (1979) Schizophrenia-like psychosis associated with anticonvulsant toxicity. Am J Psychiatry 136:973–974

    Article  CAS  PubMed  Google Scholar 

  10. Lefkowitch MM (1969) Effects of diphenylhydantoin on disruptive behavior. Arch Gen Psychiatry 20:643–651

    Article  Google Scholar 

  11. Post RM, Weiss SRB, Chuang DM et al (1994) Mechanisms of action of carbamazepine in seizures and affective disorders. In: Joffe RT, Calabrse JR (eds) Anticonvulsant in psychiatry. Marcel Dekker, New York, NY, pp 43–92

    Google Scholar 

  12. Fenwick PB (1992) Antiepileptic drugs and their psychotropic effects. Epilepsia 33(Suppl 6):S33–S36

    PubMed  Google Scholar 

  13. Gillham RA, Williams N, Wiedmann K et al (1988) Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J Neurol Neurosurg Psychiatry 51:929–933

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Smith DB, Mattson RH, Cramer JA et al (1987) Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 28(Suppl 3):S50–S58

    Article  PubMed  Google Scholar 

  15. Keene DL, Whiting S, Humphreys P (1990) Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 17:317–319

    Article  CAS  PubMed  Google Scholar 

  16. Prevey ML, Mattson RH, Cramer JA (1989) Improvement in cognitive functioning and mood state after conversion to valproate monotherapy. Neurology 39:1640–1641

    Article  CAS  PubMed  Google Scholar 

  17. Boxer CM, Herzberg JL, Scott DF (1976) Has sodium valproate hypnotic effects? Epilepsia 17:367–370

    Article  CAS  PubMed  Google Scholar 

  18. Sommerberg KW, Theilgaard A, Rasmussen KL et al (1977) Valproate sodium: evaluation of so-called psychotropic effects: a controlled study. Epilepsia 18:159–167

    Article  Google Scholar 

  19. Vining EP, Mellitis ED, Dorsen MM et al (1987) Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 80:165–174

    CAS  PubMed  Google Scholar 

  20. Kastner T, Friedman DL, Plummer AT et al (1990) Valproic acid for the treatment of children with mental retardation and mood symptomatology. Pediatrics 86:467–472

    CAS  PubMed  Google Scholar 

  21. Herranz JL, Arteaga R, Armijo JA (1982) Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients. Epilepsia 23:203–214

    Article  CAS  PubMed  Google Scholar 

  22. Gören MZ, Onat F (2007) Ethosuximide: from bench to bedside. CNS Drug Rev 13:224–239

    Article  PubMed  Google Scholar 

  23. Smith WL, Philippus MJ, Guard HL (1968) Psychometric study of children with learning problems and 14-6 positive spike EEG patterns, treated with ethosuximide (Zarontin) and placebo. Arch Dis Child 43:616–619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sirven JI, Fife TD, Wingerchuk DM et al (2007) Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clin Proc 82:40–47

    Article  CAS  PubMed  Google Scholar 

  25. Martyn-St James M, Glanville J, McCool R et al (2012) The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Seizure 21:665–678

    Article  PubMed  Google Scholar 

  26. Bourgeois BF (1997) Felbamate. Semin Pediatr Neurol 4:3–8

    Article  CAS  PubMed  Google Scholar 

  27. McConnell H, Snyder PJ, Duffy JD et al (1996) Neuropsychiatric side effects related to treatment with felbamate. J Neuropsychiatry Clin Neurosci 8:341–346

    Article  CAS  PubMed  Google Scholar 

  28. Hill RR, Stagno SJ, Tesar GE (1995) Secondary mania associated with the use of felbamate. Psychosomatics 36:404–406

    Article  CAS  PubMed  Google Scholar 

  29. Gay PE, Mecham GF, Coskey JS et al (1995) Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Psychol Rep 77:1208–1210

    Article  CAS  PubMed  Google Scholar 

  30. Sokolski KN, Green C, Maris DE et al (1999) Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 11:217–222

    Article  CAS  PubMed  Google Scholar 

  31. Marson AG, Kadir ZA, Hutton JL et al (1997) The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38:859–880

    Article  CAS  PubMed  Google Scholar 

  32. Crawford P (1998) An audit of topiramate use in a general neurology clinic. Seizure 7:207–211

    Article  CAS  PubMed  Google Scholar 

  33. Holmes GL (1997) Gabapentin for treatment of epilepsy in children. Semin Pediatr Neurol 4:244–250

    Article  CAS  PubMed  Google Scholar 

  34. Mikati MA, Choueri R, Khurana DS et al (1998) Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 42(Suppl 1):57–62

    PubMed  Google Scholar 

  35. Besag FMC (1996) Gabapentin use with pediatric patients. Rev Contemp Pharmacother 7:233–238

    CAS  Google Scholar 

  36. Dimond KR, Pande AC, Lamoreaux L et al (1996) Effect of gabapentin (NeurontinR) on mood and well-being in patients with epilepsy. Prog Neuro Psychopharmacol Biol Psychiatry 20:407–417

    Article  CAS  Google Scholar 

  37. Meador KJ, Loring DW, Ray PG et al (1999) Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 40:1279–1285

    Article  CAS  PubMed  Google Scholar 

  38. Mula M, Sander JW (2007) Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 30:555–567

    Article  CAS  PubMed  Google Scholar 

  39. Meador KJ, Loring DW, Ray PG et al (2001) Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 56:1177–1182

    Article  CAS  PubMed  Google Scholar 

  40. Besag FM, Wallace SJ, Dulac O et al (1995) Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 127:991–997

    Article  CAS  PubMed  Google Scholar 

  41. Smith D, Baker G, Davies G et al (1993) Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34:312–322

    Article  CAS  PubMed  Google Scholar 

  42. Brodie MJ, Richens A, Yuen AW (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 345:476–479

    Article  CAS  PubMed  Google Scholar 

  43. Aldenkamp AP, Arends J, Bootsma HP et al (2002) Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 43:19–26

    Article  CAS  PubMed  Google Scholar 

  44. Schapel G, Chadwick DA (1996) Survey comparing lamotrigine and vigabatrin in everyday clinical practice. Seizure 5:267–270

    Article  CAS  PubMed  Google Scholar 

  45. Rigo JM, Hans G, Nguyen L et al (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136:659–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Sirsi D, Safdieh JE (2007) The safety of levetiracetam. Expert Opin Drug Saf 6:241–250

    Article  CAS  PubMed  Google Scholar 

  47. Goldberg-Stern H, Feldman L, Eidlitz-Markus T et al (2013) Levetiracetam in children, adolescents and young adults with intractable epilepsy: efficacy, tolerability and effect on electroencephalogram--a pilot study. Eur J Paediatr Neurol 17:248–253

    Article  PubMed  Google Scholar 

  48. Cramer JA, Fisher R, Ben-Menachem E et al (1999) New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40:590–600

    Article  CAS  PubMed  Google Scholar 

  49. Mula M, Trimble MR, Lhatoo SD et al (2003) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44:659–663

    Article  PubMed  Google Scholar 

  50. Marcotte D (1998) Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 50:245–251

    Article  CAS  PubMed  Google Scholar 

  51. Crawford P, Meinardi H, Brown S et al (2001) Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Epilepsia 42:531–538

    Article  CAS  PubMed  Google Scholar 

  52. Sackellares JC, Krauss G, Sommerville KW et al (2002) Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia 43:394–398

    Article  CAS  PubMed  Google Scholar 

  53. Leach JP, Brodie MJ (1998) Tiagabine. Lancet 351:203–207

    Article  CAS  PubMed  Google Scholar 

  54. Leppik IE (1995) Tiagabine: the safety landscape. Epilepsia 36(Suppl 6):S10–S13

    Article  CAS  PubMed  Google Scholar 

  55. Constable S, Pirmohamed M (2004) Drugs and the retina. Expert Opin Drug Saf 3:249–259

    Article  CAS  PubMed  Google Scholar 

  56. Sander JW, Hart YM, Trimble MR et al (1991) Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 54:435–439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Caviedes BE, Herranz JL, Arteaga R et al (1999) In children with refractory epilepsy: vigabatrin or lamotrigine? Rev Neurol 28:444–448

    CAS  PubMed  Google Scholar 

  58. Levinson DF, Devinsky O (1999) Psychiatric adverse events during vigabatrin therapy. Neurology 53:1503–1511

    Article  CAS  PubMed  Google Scholar 

  59. Dodrill CB, Arnett JL, Sommerville KW et al (1995) Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 36:164–173

    Article  CAS  PubMed  Google Scholar 

  60. Schmidt D, Jacob R, Loiseau P et al (1993) Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 15:67–73

    Article  CAS  PubMed  Google Scholar 

  61. Sackellares JC, Ramsay RE, Wilder BJ et al (2004) Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 45:610–617

    Article  CAS  PubMed  Google Scholar 

  62. Faught E, Ayala R, Montouris GG et al (2001) Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57:1774–1779

    Article  CAS  PubMed  Google Scholar 

  63. Zaccara G, Giovannelli F, Maratea D et al (2013) Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure 22:528–536

    Article  PubMed  Google Scholar 

  64. Arroyo S, Anhut H, Kugler AR et al (2004) Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45:20–27

    Article  CAS  PubMed  Google Scholar 

  65. Faulkner MA, Burke RA (2013) Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Expert Opin Drug Saf 12:847–855

    Article  CAS  PubMed  Google Scholar 

  66. Resor SR Jr, Resor LD (1990) Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 40:1677–1681

    Article  PubMed  Google Scholar 

  67. Shorvon SD (1996) Safety of topiramate: adverse events and relationships to dosing. Epilepsia 37(Suppl 2):S18–S22

    Article  CAS  PubMed  Google Scholar 

  68. Zaccara G, Tramacere L, Cincotta M (2011) Drug safety evaluation of zonisamide for the treatment of epilepsy. Expert Opin Drug Saf 10:623–631

    Article  CAS  PubMed  Google Scholar 

  69. Brickel N, Gandhi P, VanLandingham K et al (2012) The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia 53:606–612

    Article  CAS  PubMed  Google Scholar 

  70. Zaccara G, Franciotta D, Perucca E (2007) Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48:1223–1244

    Article  CAS  PubMed  Google Scholar 

  71. Błaszczyk B, Lasoń W, Czuczwar SJ (2015) Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep 67:426–434

    Article  PubMed  CAS  Google Scholar 

  72. Mockenhaupt M, Messenheimer J, Tennis P et al (2005) Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64:1134–1138

    Article  CAS  PubMed  Google Scholar 

  73. Chung WH, Hung SI, Hong HS et al (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486

    Article  CAS  PubMed  Google Scholar 

  74. Anderson GD (2004) Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 43(Suppl 3):53–59

    Google Scholar 

  75. Bryant AE 3rd, Dreifuss FE (1996) Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46:465–469

    Article  PubMed  Google Scholar 

  76. Pellock JM (1999) Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 21:225–239

    Article  CAS  PubMed  Google Scholar 

  77. Handoko KB, Souverein PC, van Staa TP et al (2006) Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 47:1232–1236

    Article  PubMed  Google Scholar 

  78. Kaufman DW, Kelly JP, Anderson T et al (1997) Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 38:1265–1269

    Article  CAS  PubMed  Google Scholar 

  79. Ibáñez L, Vidal X, Ballarín E et al (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165:869–874

    Article  PubMed  Google Scholar 

  80. Pack A (2008) Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 17:181–186

    Article  PubMed  Google Scholar 

  81. Brodie MJ, Mintzer S, Pack AM et al (2013) Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54:11–27

    Article  CAS  PubMed  Google Scholar 

  82. Pack AM (2011) Treatment of epilepsy to optimize bone health. Curr Treat Options Neurol 13:346–354

    Article  PubMed  Google Scholar 

  83. Svalheim S, Sveberg L, Mochol M et al (2015) Interactions between antiepileptic drugs and hormones. Seizure 28:12–17

    Article  PubMed  Google Scholar 

  84. Svalheim S, Taubøll E, Luef G et al (2009) Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav 16:281–287

    Article  PubMed  Google Scholar 

  85. Isojärvi JI, Löfgren E, Juntunen KS et al (2004) Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 62:247–253

    Article  PubMed  CAS  Google Scholar 

  86. Isojärvi JI, Taubøll E, Pakarinen AJ et al (2001) Altered ovarian function and cardiovascular risks in valproate treated women. Am J Med 111:290–296

    Article  PubMed  Google Scholar 

  87. Isojarvi JIT, Turkka J, Pakarinen AJ et al (2001) Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for Epilepsy. Epilepsia 42:930–934

    Article  CAS  PubMed  Google Scholar 

  88. Tiihonen M, Liewendahl K, Waltimo O et al (1995) Thyroid status of patients receiving long-term anticonvulsant therapy assessed by peripheral parameters: a placebo-controlled thyroxine therapy trial. Epilepsia 36:1118–1125

    Article  CAS  PubMed  Google Scholar 

  89. Mintzer S, Skidmore CT, Abidin CJ et al (2009) Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 65:448–456

    Article  CAS  PubMed  Google Scholar 

  90. Biton V (2003) Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 17:781–791

    Article  CAS  PubMed  Google Scholar 

  91. Maguire MJ, Hemming K, Wild JM et al (2010) Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 51:2423–2431

    Article  PubMed  Google Scholar 

  92. Velez-Ruiz NJ, Meador KJ (2015) Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Saf 38:271–278

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Sankar R, Lerner JT (2008) Teratogenicity of antiepileptic drugs: role of pharmacogenomics. Int Rev Neurobiol 83:215–225

    Article  PubMed  Google Scholar 

  94. Vajda FJ, O’Brien TJ, Graham J et al (2016) Is carbamazepine a human teratogen? J Clin Neurosci 23:34–37

    Article  CAS  PubMed  Google Scholar 

  95. Adab N, Tudur Smith C, Vinten J (2015) WITHDRAWN: common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev (12): CD004848

    Google Scholar 

  96. Meador KJ, Baker GA, Browning N et al (2009) NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360:1597–1605

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Meador KJ, Baker GA, Browning N et al (2012) NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 78:1207–1214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Meador KJ, Baker GA, Browning N et al (2013) NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244–252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Reinisch JM, Sanders SA, Mortensen EL et al (1995) In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 274:1518–1525

    Article  CAS  PubMed  Google Scholar 

  100. Scolnik D, Nulman I, Rovet J et al (1994) Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271:767–770

    Article  CAS  PubMed  Google Scholar 

  101. Rogawski M (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69:273–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Lasoń W, Dudra-Jastrzębska M, Rejdak K et al (2011) Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep 63:271–292

    Article  PubMed  Google Scholar 

  103. Rambeck B, May TW (2005) Interaction between antiepileptic drugs. In: Majkowski J, Bourgeois B, Patsalos P, Mattson R (eds) Antiepileptic drugs. Combination therapy and interaction. Cambridge University Press, Cambridge, pp 111–138

    Chapter  Google Scholar 

  104. Crawford P (2002) Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16:263–272

    Article  CAS  PubMed  Google Scholar 

  105. Perucca E (2006) Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 45:351–363

    Article  CAS  PubMed  Google Scholar 

  106. Schmidt D (2011) AED discontinuation may be dangerous for seizure-free patients. J Neural Transm (Vienna) 118:183–186

    Article  Google Scholar 

  107. Beghi E (2001) AED discontinuation may not be dangerous in seizure-free patients. J Neural Transm (Vienna) 118:187–191

    Article  Google Scholar 

  108. Lie IA, Hoggen I, Samsonsen C et al (2015) Treatment non-adherence as a trigger for status epilepticus: an observational, retrospective study based on therapeutic drug monitoring. Epilepsy Res 113:28–33

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the Ministry of Education (LH 15025) and the Czech Science Foundation (16-04726S). Support for the long-term conceptual development of this research organization was supported by RVO: 67985823.

Author information

Authors and Affiliations

  1. Institute of Physiology, Czech Academy of Sciences, Videnska 1023, 142 20, Prague 4 Krc, Czech Republic

    Hana Kubova

Authors
  1. Hana Kubova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hana Kubova .

Editor information

Editors and Affiliations

  1. Laboratorio de Investigación y Desarrollo de Bioactivos (LIDeB) Faculty of Exact Sciences, National University of La Plata, La Plata, Buenos Aires, Argentina

    Alan Talevi

  2. Department of Pharmacobiology, Center for Research and Advanced Studies, Mexico City, Mexico

    Luisa Rocha

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Kubova, H. (2016). Side Effects of Antiepileptic Drugs. In: Talevi, A., Rocha, L. (eds) Antiepileptic Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6355-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6355-3_17

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6353-9

  • Online ISBN: 978-1-4939-6355-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation